Lilly Makes Billions of Weight-Loss Pills
Digest more
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...
This week's dividend activity included increased payouts from Visa ( V) and Marathon Petroleum ( MRC) as well as declarations ...
Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The ...
Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback